There’s good news for people with severe treatment-resistant depression: Esketamine is a groundbreaking therapy that can provide relief from major depression within hours.

5 days ago · A study by Johnson & Johnson, the company that makes Spravato, showed that 22.5% of people using esketamine nasal spray achieved remission from major depression in four weeks. Just 7.6% of people ...

4 days ago · The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression. Spravato was first approved for use in 2019 to treat people with major depressive disorder who did not respond to ...

Jan 21, 2025 · SPRAVATO ® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression Following U.S. FDA Priority Review, approval is based on data demonstrating SPRAVATO ® alone met its primary endpoint at 4 weeks and led to rapid and superior improvement in depressive symptoms compared to placebo as early as 24 hours 1

Objective: Intranasal esketamine has been approved as an adjunctive therapy for treatment-resistant major depressive disorder with acute suicidal ideation and behavior. The authors conducted a systematic review and meta-analysis of the available data on its efficacy against depression and suicidality as well as its side effects.

4 days ago · Objective: Intranasal esketamine has been approved as an adjunctive therapy for treatment-resistant major depressive disorder with acute suicidal ideation and behavior. The authors conducted a systematic review and meta-analysis of the available data on its efficacy against depression and suicidality as well as its side effects. Methods: MEDLINE was searched with the keyword “esketamine ...

Esketamine nasal spray is recommended for adults diagnosed with major depressive disorder (MDD) who did not respond to at least two antidepressants, and who currently have a major depressive episode of moderate or severe intensity (1, 6).

Sep 1, 2024 · Esketamine nasal spray is used together with an antidepressant taken by mouth, to treat patients with depression who have previously received at least 2 antidepressant treatments that did not work well (treatment-resistant depression).

Jul 12, 2019 · It is the only fast-acting FDA-approved antidepressant available for hard-to-treat depression that works to ease depression symptoms, as well as suicidal thoughts and tendencies. For the right type of patient, there is great promise that esketamine can offer help for depression and lower the risk of suicide where other treatment options have ...

Oct 4, 2023 · In this trial involving patients with treatment-resistant depression, esketamine nasal spray was superior to the comparator, extended-release quetiapine, a commonly used antipsychotic...